Gerard Griffioen
Hoofd Techniek/Wetenschap/O&O bij reMYND NV
Profiel
Gerard Griffioen is currently the Chief Scientific Officer-Drug Discovery at reMYND NV.
He previously worked as a Principal at the University of Vienna and Katholieke Universiteit Leuven.
Dr. Griffioen obtained a doctorate degree from Vrije Universiteit Amsterdam in 1996.
Actieve functies van Gerard Griffioen
Bedrijven | Functie | Begin |
---|---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Hoofd Techniek/Wetenschap/O&O | - |
Eerdere bekende functies van Gerard Griffioen
Bedrijven | Functie | Einde |
---|---|---|
Katholieke Universiteit Leuven | Corporate Officer/Principal | - |
University of Vienna | Corporate Officer/Principal | - |
Opleiding van Gerard Griffioen
Vrije Universiteit Amsterdam | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |